These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31668972)

  • 21. Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.
    Deng YH; Xu D; Su YX; Cheng YJ; Yang YL; Wang XY; Zhang J; You QD; Sun LP
    Chem Biodivers; 2015 Apr; 12(4):528-37. PubMed ID: 25879498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Dioxino[2,3-f]quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice.
    Fan H; Wei D; Zheng K; Qin X; Yang L; Yang Y; Duan Y; Xu Y; Hu L
    Eur J Med Chem; 2019 Aug; 175():349-356. PubMed ID: 31096155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.
    Elsayed NMY; Serya RAT; Tolba MF; Ahmed M; Barakat K; Abou El Ella DA; Abouzid KAM
    Bioorg Chem; 2019 Feb; 82():340-359. PubMed ID: 30428414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2.
    Wei D; Fan H; Zheng K; Qin X; Yang L; Yang Y; Duan Y; Zhang Q; Zeng C; Hu L
    Bioorg Chem; 2019 Jul; 88():102916. PubMed ID: 31026719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.
    Shi L; Wu TT; Wang Z; Xue JY; Xu YG
    Bioorg Med Chem; 2014 Sep; 22(17):4735-44. PubMed ID: 25082515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
    Sun W; Hu S; Fang S; Yan H
    Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
    Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
    Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
    Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
    Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
    Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
    Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
    Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
    Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors.
    Wang XR; Wang S; Li WB; Xu KY; Qiao XP; Jing XL; Wang ZX; Yang CJ; Chen SW
    Eur J Med Chem; 2021 Mar; 213():113192. PubMed ID: 33493829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
    El-Helby AA; Sakr H; Eissa IH; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900178. PubMed ID: 31596514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors.
    Yin Y; Sha S; Wang YT; Wu X; Wang SF; Qiao F; Lv PC; Zhu HL
    Chem Biol Drug Des; 2015 Nov; 86(5):1323-9. PubMed ID: 26032487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers.
    Mahdy HA; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; El-Gamal KMA; El-Sharkawy A; Elhendawy MA; Radwan MM; Elsohly MA; Eissa IH
    Bioorg Chem; 2020 Jan; 94():103422. PubMed ID: 31812261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF
    Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X
    Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
    Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
    Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
    Jin F; Gao D; Wu Q; Liu F; Chen Y; Tan C; Jiang Y
    Bioorg Med Chem; 2013 Sep; 21(18):5694-706. PubMed ID: 23932071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
    Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
    Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
    Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
    J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors.
    Li SN; Xu YY; Gao JY; Yin HR; Zhang SL; Li HQ
    Bioorg Med Chem; 2015 Jul; 23(13):3221-7. PubMed ID: 26003342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.